Please login to create your UC TechAlerts.
Request a new password for
Required
HTR1F Antagonists for Treatment of Diabetes and Improvement of Peri-Transplant Beta Cell Survival and Function for Type 1 Diabetes
Brief description not available
Anti-Dpp6 Car For Targeted Regulatory T Cell Therapy For Inflammation In Pancreatic Islets And Central Nervous System
Diagnostic for Precursor Lesions of Pancreatic Cancer
These highly specific biomarkers distinguish potentially malignant mucinous cysts from benign nonmucinous cysts in the pancreas to help diagnose precursor lesions of pancreatic ductal adenocarcinoma. The biomarkers can be detected through enzymatic assays with exceptional accuracy and sensitivity.
TREATING TYPE-1 DIABETES BY PRESERVING BETA CELL FUNCTION
This invention proposes the first pharmacological treatment to prevent the onset of Type I diabetes by preventing beta cell destruction.
Generation Of Human Beta Cell Equivalents From Pluripotent Stem Cells In Vitro
This invention describes a robust method to generate functional human beta cell equivalents from pluripotent stem cells in vitro for wide applications in basic research, drug and toxicology screens and as a diabetes cell therapy.
Novel Compounds Targeting LRH-1 for Treatment of Inflammatory Bowel Disease, Type II Diabetes, Triple Negative Breast Cancer & Pancreatic Cancer
This technology contains a method for modulating the activity of the nuclear receptor LRH-1 with identified small molecule compounds that may be developed to treat inflammatory bowel disease, Type II diabetes, triple negative breast cancer and pancreatic cancer.
SALT-SPARING UREA TRANSPORT INHIBITOR DIURETICS FOR TREATMENT OF CARDIOVASCULAR AND RENAL DISORDERS
Therapeutic inhibitors of Urea Transporter A (UT-A) as highly effective diuretics with reduced risk of cardiac and neurological side effects for treatment of cardiovascular and renal disorders
NOVEL USE OF A RECOMBINANT ENDOGENOUS PROTEIN FOR THE TREATMENT OF FAT MALABSORPTION AND GASTRIC MOTILITY ISSUES
The invention is a recombinant form of an endogenous protein that can be used to increase fat absorption and modulate gastric motility.
NOVEL ANTIGEN TARGETS IN AUTOIMMUNE DISEASES (LUPUS AND TYPE I DIABETES) USEFUL FOR VACCINE DEVELOPMENT AND TREATMENT
UCSF investigators have identified novel antigens against which immune responses are induced in patients with SLE and type I diabetes. Using a proteomic approach, in addition to detecting autoantibodies to known SLE- or diabetes-associated antigens, the UCSF investigators also identified novel self-antigens that are also associated with the respective disease state. These results could provide novel approaches to the diagnosis and assessment of each of these autoimmune diseases